^
Association details:
| Biomarker: | KRAS G13 |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
Published date:
09/18/2021
Excerpt:
Patients with newly diagnosed mCRC were registered into FOCUS4 and tested for TP53 and RAS mutations...We observed that patients with KRAS codon 12/13 mutations had a significant benefit from adavosertib...An exploratory analysis showed that adavosertib had the most PFS effect in patients with KRAS codons 12/13/TP53-mutant tumors...
DOI:
10.1200/JCO.21.01435
